BR112020021412A8 - Composição lipossômica, inalável de liberação prolongada para uso no tratamento de doenças pulmonares - Google Patents

Composição lipossômica, inalável de liberação prolongada para uso no tratamento de doenças pulmonares

Info

Publication number
BR112020021412A8
BR112020021412A8 BR112020021412A BR112020021412A BR112020021412A8 BR 112020021412 A8 BR112020021412 A8 BR 112020021412A8 BR 112020021412 A BR112020021412 A BR 112020021412A BR 112020021412 A BR112020021412 A BR 112020021412A BR 112020021412 A8 BR112020021412 A8 BR 112020021412A8
Authority
BR
Brazil
Prior art keywords
treatment
inalables
liposome
liposomal composition
lung diseases
Prior art date
Application number
BR112020021412A
Other languages
English (en)
Other versions
BR112020021412A2 (pt
Inventor
Hong Keelung
fang Jonathan
TSENG Yu-Cheng
CHENG Ting-Yu
YU Wan-Ni
TANG Jo-Hsin
Original Assignee
Taiwan Liposome Co Ltd
Tlc Biopharmaceuticals Inc
Inspirmed Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiwan Liposome Co Ltd, Tlc Biopharmaceuticals Inc, Inspirmed Corp filed Critical Taiwan Liposome Co Ltd
Publication of BR112020021412A2 publication Critical patent/BR112020021412A2/pt
Publication of BR112020021412A8 publication Critical patent/BR112020021412A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

É fornecida uma composição lipossomal de liberação prolongada para uso no tratamento de doenças pulmonares. A composição de lipossomas de liberação prolongada compreende um lipossoma que inclui um lipídeo modificado por polietileno glicol (PEG) e encapsula um inibidor de tirosina quinase. O inibidor da tirosina quinase está aprisionado estavelmente no lipossoma e a formulação do fármaco lipossomal resultante pode ser aerossolizada ou nebulizada para administração por inalação. Esta formulação de fármaco lipossomal em aerossol produz perfis farmacocinéticos e farmacodinâmicos consistentes, ao mesmo tempo em que atinge a eficácia e segurança desejadas.
BR112020021412A 2018-04-23 2019-04-23 Composição lipossômica, inalável de liberação prolongada para uso no tratamento de doenças pulmonares BR112020021412A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862661217P 2018-04-23 2018-04-23
US62/661,217 2018-04-23
PCT/US2019/028647 WO2019209787A1 (en) 2018-04-23 2019-04-23 Inhalable liposomal sustained release composition for use in treating pulmonary diseases

Publications (2)

Publication Number Publication Date
BR112020021412A2 BR112020021412A2 (pt) 2021-01-19
BR112020021412A8 true BR112020021412A8 (pt) 2022-07-05

Family

ID=66821301

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020021412A BR112020021412A8 (pt) 2018-04-23 2019-04-23 Composição lipossômica, inalável de liberação prolongada para uso no tratamento de doenças pulmonares

Country Status (12)

Country Link
US (2) US11534399B2 (pt)
EP (1) EP3784213B1 (pt)
JP (1) JP7391039B2 (pt)
KR (1) KR20210003197A (pt)
CN (1) CN112004527A (pt)
AU (1) AU2019261329A1 (pt)
BR (1) BR112020021412A8 (pt)
CA (1) CA3101102A1 (pt)
ES (1) ES2964413T3 (pt)
IL (1) IL278079A (pt)
TW (1) TW202011941A (pt)
WO (1) WO2019209787A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021536474A (ja) * 2018-09-10 2021-12-27 タイワン リポソーム カンパニー リミテッド 徐放性眼科用医薬組成物およびその使用
US20220211621A1 (en) * 2019-04-25 2022-07-07 Tlc Biopharmaceuticals, Inc. Liposomal sustained-release compositions containing a therapeutic drug and use thereof
AU2021244195A1 (en) * 2020-03-22 2022-09-15 Inspirmed Corp. Composition of antiviral agent for use in prophylactic or post-exposure treatment of infectious or respiratory diseases
CN112472791A (zh) * 2020-11-16 2021-03-12 复旦大学 CsA脂质体在制备抗SARS-CoV-2药物中的应用
KR20230026963A (ko) * 2021-08-18 2023-02-27 주식회사 삼양홀딩스 룩소리티닙의 경구용 정제 조성물 및 이의 제조 방법
KR102348901B1 (ko) 2021-08-26 2022-01-07 충북대학교 산학협력단 레고라페닙을 유효성분으로 포함하는 만성폐쇄성 폐질환의 예방 또는 치료용 조성물
WO2023182512A1 (ja) * 2022-03-25 2023-09-28 国立研究開発法人医薬基盤・健康・栄養研究所 特発性肺線維症の治療または予防剤
WO2024067849A1 (zh) * 2022-09-30 2024-04-04 上海济煜医药科技有限公司 一种脂质体药物组合物及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986006959A1 (en) 1985-05-22 1986-12-04 Liposome Technology, Inc. Liposome inhalation method and system
IE63869B1 (en) 1986-11-06 1995-06-14 Res Dev Foundation Aerosols containing liposomes and method for their preparation
US5958378A (en) 1996-07-03 1999-09-28 Research Development Foundation High dose liposomal aerosol formulations containing cyclosporin A or budesonide
GB9912639D0 (en) 1999-05-28 1999-07-28 Britannia Pharmaceuticals Ltd Improvements in and relating to treatment of respiratory conditions
DE10214983A1 (de) 2002-04-04 2004-04-08 TransMIT Gesellschaft für Technologietransfer mbH Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
ES2439727T3 (es) 2002-10-29 2014-01-24 Insmed Incorporated Liberación sostenida de antiinfectantes
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
KR20060015265A (ko) * 2003-05-30 2006-02-16 알자 코포레이션 제제의 폐 투여 방법
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
CA2838111C (en) 2005-12-08 2016-01-19 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US8119156B2 (en) 2006-10-24 2012-02-21 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8268347B1 (en) 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8071127B2 (en) 2006-10-24 2011-12-06 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
WO2009040426A1 (en) * 2007-09-28 2009-04-02 Universitätsspital Basel Immunoliposomes for treatment of cancer
WO2012027727A2 (en) * 2010-08-26 2012-03-01 Kunyuan Cui Lipomacrocycles and uses thereof
US20130216608A1 (en) * 2010-09-09 2013-08-22 Trifoilium Aps Airway Administration of Angiogenesis Inhibitors
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
DK3922241T3 (da) * 2013-02-01 2023-12-04 Celator Pharmaceuticals Inc Fjernladning af svært vandopløselige lægemidler i liposomer
CA3172586A1 (en) * 2013-07-31 2015-02-05 Avalyn Pharma Inc. Aerosol imatininb compounds and uses thereof
KR20150026613A (ko) * 2013-09-03 2015-03-11 삼성전자주식회사 소수성 물질 및 조영제를 포함하는 리포좀 및 그의 용도
NZ722927A (en) 2014-01-10 2022-07-29 Avalyn Pharma Inc Aerosol pirfenidone and pyridone analog compounds and uses thereof
WO2016178064A1 (en) 2015-05-06 2016-11-10 Suven Life Sciences Limited Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof
EP3352733A1 (en) * 2015-09-21 2018-08-01 Mallinckrodt LLC Improved stability of liposome formulations and uses thereof
AU2017206077B2 (en) * 2016-01-08 2021-11-18 The Regents Of The University Of California Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery
SG11201805375PA (en) * 2016-02-04 2018-07-30 Stem Cell Theranostics Inc Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity

Also Published As

Publication number Publication date
EP3784213C0 (en) 2023-09-06
IL278079A (en) 2020-11-30
EP3784213A1 (en) 2021-03-03
BR112020021412A2 (pt) 2021-01-19
WO2019209787A1 (en) 2019-10-31
CA3101102A1 (en) 2019-10-31
US20230088661A1 (en) 2023-03-23
US11534399B2 (en) 2022-12-27
TW202011941A (zh) 2020-04-01
KR20210003197A (ko) 2021-01-11
JP7391039B2 (ja) 2023-12-04
JP2021522163A (ja) 2021-08-30
ES2964413T3 (es) 2024-04-05
CN112004527A (zh) 2020-11-27
US20210145740A1 (en) 2021-05-20
EP3784213B1 (en) 2023-09-06
AU2019261329A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
BR112020021412A8 (pt) Composição lipossômica, inalável de liberação prolongada para uso no tratamento de doenças pulmonares
Schug et al. Fentanyl formulations in the management of pain: an update
NZ603686A (en) Topical formulation for a jak inhibitor
Ong et al. In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation
CR7362A (es) Formulaciones farmaceuticas de derivado de platino
AR057946A1 (es) Formulacion de zonisamida de liberacion sostenidda
BR0312268A (pt) Dispositivos transdermais para liberação de droga que têm microprotrusões revestidas
BRPI0510936A (pt) formulações com liberação controlada de substáncia ativa, contendo vardenafil
MX2021010359A (es) Una composicion farmaceutica para reducir la grasa localizada y sus usos.
UY31867A (es) Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
PL379867A1 (pl) Układ dostarczania o kontrolowanym uwalnianiu do podawania donosowego
EA200900264A1 (ru) Композиции флибансерина и способ их приготовления
CO2021008988A2 (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
AR058194A1 (es) Medicamentos que comprenden un agente antimuscarinico y un corticoesteroide
BRPI0510760A (pt) método para administrar a um paciente uma composição, composição tópica, e, emplastro
BR112015008076A2 (pt) composição farmacêutica, e, método de preparar uma composição
BR112015030140A2 (pt) forma de dosagem farmacêutica sólida para liberação de pelo menos um ingrediente farmacêutico ativo na cavidade oral
BR112017016087A2 (pt) formulações para coxim articular adiposo e métodos de uso das mesmas
CY1114251T1 (el) Χρηση ενος συνδυασμου ο οποιος περιλαμβανει l-kapnitinh ή αλκανοϋλ l-kapnitinh, λιποδιαλυτη βενζοκινονη και ωμεγα-3-πολυακορεστο λιπαρο οξυ για την παρασκευη ενος διαιτητικου συμπληρωματος ή φαρμακου για τη θεραπευτικη αγωγη παθησεων του κερατοειδους
BRPI0607172A2 (pt) método para a ministração de pelo menos uma substáncia farmaceuticamente ativa a um paciente, combinação de medicamentos e uso de pelo menos uma substáncia farmaceuticamente ativa para a fabricação de uma combinação de medicamentos
BRPI0406858A (pt) Liberação controlada de agentes altamente solúveis
BRPI0506630A (pt) composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada
BR112015029709A2 (pt) dihidroetorfina para o fornecimento de alívio da dor e anestesia
CY1124964T1 (el) Τοπικη συνθεση για την θεραπευτικη αντιμετωπιση δερματικων διαταραχων συμπεριλαμβανομενης της ανδρικης τριχοπτωσης
BR112014027653A2 (pt) formulações para a liberação dos ingredientes ativos

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: INSPIRMED CORP. (TW)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]